Breaking News Instant updates and real-time market news.

RAMP

LiveRamp

$44.06

0.27 (0.62%)

08:17
02/12/19
02/12
08:17
02/12/19
08:17

LiveRamp's 'not perfect' FY20 view gets guidance risk out of way, says Stephens

Stephens analyst Brett Huff said LiveRamp reported a "great quarter," but gave FY20 guidance that "was not perfect," with 28% revenue growth at the midpoint versus the consensus expectation for 30% growth. However, he thinks this gets guidance risk "out of the way" and cites the company's typical conservatism. The analyst, who sees revenue growth remaining the key driver of LiveRamp shares, reiterates an Overweight rating and $52 price target on the stock.

  • 03

    Mar

RAMP LiveRamp
$44.06

0.27 (0.62%)

10/30/18
SPHN
10/30/18
NO CHANGE
Target $55
SPHN
Overweight
LiveRamp selloff overdone following analyst day, says Stephens
Stephens analyst Brett Huff views LiveRamp as a unique early-stage SaaS growth story with an already leading market share and he believes the selloff in its shares following the company's analyst day was overdone. He now thinks near to medium-term stock value creation is more tilted toward management demonstrating it growth drivers and business defensibility over a potential takeout, though he believes both "will happen over time." Huff, who thinks LiveRamp can keep winning in the marketplace, keeps an Overweight rating and $55 price target on the shares.
12/21/18
WELS
12/21/18
INITIATION
Target $60
WELS
Outperform
LiveRamp resumed with an Outperform at Wells Fargo
Wells Fargo analyst Robert Coolbrith resumed coverage of LiveRamp with an Outperform rating and $60 price target. In a research note to investors, Coolbrith says he expects LiveRamp will sustain robust revenue growth, with a 39% revenue growth CAGR through F2024, while significantly expanding non-GAAP operating margin to management's long-term target of 25%. He believes LiveRamp remains in the early stages of penetrating global brands and driving engagement with its own client base and views the company as s strong defensive play amid an increasingly uncertain macro outlook.
02/06/19
WBLR
02/06/19
NO CHANGE
WBLR
Outperform
William Blair says advanced TV opportunity not priced into LiveRamp shares
LiveRamp's tie-in to the "burgeoning addressable/streaming market should help the stock reaccelerate," William Blair analyst Adam Klauber tells investors in a research note. He believes the advanced TV segment, over the next several years, has the potential to push the company's overall revenue growth to 30% or above. LiveRamp is showing early signs of success in a market that could effectively increase its total addressable market by roughly 50%-plus over the longer term, says the analyst. Klauber recommends investors take a fresh look at LiveRamp shares "since the promising addressable/streaming dynamics do not appear to be built into the valuation." The analyst thinks data points showing that the advanced TV market is taking off have the potential to result in 50%-plus upside in shares of LiveRamp over the next two years.

TODAY'S FREE FLY STORIES

CHRA

Charah Solutions

$6.80

0.005 (0.07%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Downgrade
Charah Solutions rating change  »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONE

CyrusOne

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Downgrade
CyrusOne rating change  »

Jefferies downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

ARAY

Accuray

$5.26

0.09 (1.74%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Hot Stocks
Accuray reports results from SBRT trial »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.31

-0.35 (-0.54%)

07:36
02/22/19
02/22
07:36
02/22/19
07:36
Upgrade
Citi rating change  »

Jefferies sees positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

BCLI

BrainStorm

$3.88

0.01 (0.26%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Hot Stocks
BrainStorm announces first U.S.clinical site for Phase 2 MS study »

BrainStorm announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Earnings
Breaking Earnings news story on W.P. Carey »

W.P. Carey sees FY19 AFFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Recommendations
Keysight Technologies analyst commentary  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

, KR

Kroger

$28.55

-0.2 (-0.70%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

KR

Kroger

$28.55

-0.2 (-0.70%)

I

Intelsat

$24.59

0.5 (2.08%)

BSX

Boston Scientific

$40.12

-0.01 (-0.02%)

OAS

Oasis Petroleum

$6.07

-0.28 (-4.41%)

MNST

Monster Beverage

$58.87

0.16 (0.27%)

LKQ

LKQ Corp.

$27.33

0.36 (1.33%)

DK

Delek US

$36.18

-0.8953 (-2.41%)

AGI

Alamos Gold

$4.82

-0.055 (-1.13%)

APEI

American Public Education

$32.93

0.88 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 28

    Mar

  • 18

    May

  • 22

    May

  • 28

    May

07:35
02/22/19
02/22
07:35
02/22/19
07:35
General news
Treasury Market Outlook: yields are lower in the U.S. and Europe »

Treasury Market Outlook:…

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
W.P. Carey reports Q4 AFFO $1.33, consensus $1.33 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BXG

Bluegreen Vacations

$13.92

-0.12 (-0.85%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TEF

Telefonica

$8.85

0.12 (1.37%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
EU says Telefonica breached commitment in E-Plus acquisition »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CONE

CyrusOne

$52.44

-4.75 (-8.31%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Recommendations
CyrusOne analyst commentary  »

CyrusOne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

BIIB

Biogen

$320.99

-14.02 (-4.18%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
Insmed sees FY19 ARIKAYCE revenues $80M-$90M »

Insmed expects cash-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OPNT

Opiant Pharmaceuticals

$14.65

-0.25 (-1.68%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Recommendations
Opiant Pharmaceuticals analyst commentary  »

Opiant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$418.66

-3.9 (-0.92%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Downgrade
Regeneron rating change  »

Regeneron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

  • 11

    Mar

  • 28

    Apr

  • 13

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Earnings
Insmed reports Q4 EPS ($1.19), consensus ($1.06) »

Reports Q4 revenue $9.8M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SHW

Sherwin-Williams

$438.49

0.56 (0.13%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Recommendations
Sherwin-Williams analyst commentary  »

Sherwin-Williams price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$47.88

0.35 (0.74%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Initiation
Zogenix initiated  »

Zogenix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$10.03

-0.07 (-0.69%)

, JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$10.03

-0.07 (-0.69%)

JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

M

Macy's

$24.44

-0.58 (-2.32%)

CZR

Caesars

$9.42

-0.21 (-2.18%)

KEM

Kemet

$18.87

-0.56 (-2.88%)

COUP

Coupa Software

$92.20

-1.55 (-1.65%)

SM

SM Energy

$17.01

-2.69 (-13.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 03

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

ROKU

Roku

$51.47

-2.16 (-4.03%)

07:29
02/22/19
02/22
07:29
02/22/19
07:29
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SM

SM Energy

$17.01

-2.69 (-13.65%)

07:29
02/22/19
02/22
07:29
02/22/19
07:29
Recommendations
SM Energy analyst commentary  »

SM Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$79.82

0.38 (0.48%)

07:28
02/22/19
02/22
07:28
02/22/19
07:28
Initiation
Merck initiated  »

Merck initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

  • 18

    May

  • 17

    Jun

SAGE

Sage Therapeutics

$146.14

-1.32 (-0.90%)

07:28
02/22/19
02/22
07:28
02/22/19
07:28
Initiation
Sage Therapeutics initiated  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.